FDA Approves INVOKAMET XR — Janssen Pharmaceuticals, Inc.

Janssen Pharmaceuticals, Inc. secured FDA approval for the brand-name formulation of Invokamet XR (canagliflozin and metformin hydrochloride) today, expanding the availability of the extended-release fixed-dose combination for type 2 diabetes. This launch strengthens the company's standing in the rapidly growing SGLT2 inhibitor market and introduces a differentiated orRALLY competitor designed to support patient adherence through simplified dosing regimens.